Inhibrx (INBX) News Today $11.79 -0.09 (-0.76%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$11.80 +0.02 (+0.13%) As of 04/15/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Arbiter Partners Capital Management LLC Purchases Shares of 28,095 Inhibrx, Inc. (NASDAQ:INBX)Arbiter Partners Capital Management LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 28,095 shares of the company's stock, valued at approximatelyApril 10, 2025 | marketbeat.com36,195 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Yakira Capital Management Inc.Yakira Capital Management Inc. bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,195 shares of the company's stock, valued aApril 8, 2025 | marketbeat.comRangeley Capital LLC Takes $761,000 Position in Inhibrx, Inc. (NASDAQ:INBX)Rangeley Capital LLC bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 49,401 shares of the company's stock, valued at approximately $April 5, 2025 | marketbeat.comSlotnik Capital LLC Acquires New Holdings in Inhibrx, Inc. (NASDAQ:INBX)Slotnik Capital LLC acquired a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 388,000 shares of the company's stock, valued at approximatelyApril 5, 2025 | marketbeat.comInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comCharles Schwab Investment Management Inc. Invests $503,000 in Inhibrx, Inc. (NASDAQ:INBX)Charles Schwab Investment Management Inc. acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 32,657 shares of the company's stock, valued at appApril 2, 2025 | marketbeat.comInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentApril 1, 2025 | prnewswire.comShort Interest in Inhibrx, Inc. (NASDAQ:INBX) Declines By 19.7%Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 955,400 shares, a decrease of 19.7% from the February 28th total of 1,190,000 shares. Currently, 9.6% of the company's shares are short sold. Based on an average daily volume of 91,300 shares, the days-to-cover ratio is currently 10.5 days.April 1, 2025 | marketbeat.com20,492 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Corient Private Wealth LLCCorient Private Wealth LLC purchased a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,492 shares of the company's stock, valued at approximatelyMarch 31, 2025 | marketbeat.com51,445 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,445 shares of the company's stock, valMarch 26, 2025 | marketbeat.comMeridian Wealth Advisors LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)Meridian Wealth Advisors LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company's stock, valued at approximately $385,000. MeMarch 24, 2025 | marketbeat.comInhibrx Biosciences Full Year 2024 Earnings: Beats ExpectationsMarch 19, 2025 | finance.yahoo.comInhibrx (NASDAQ:INBX) Releases Earnings Results, Misses Expectations By $0.21 EPSInhibrx (NASDAQ:INBX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter.March 19, 2025 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 18, 2025 | finanznachrichten.deInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 17, 2025 | prnewswire.comHighTower Advisors LLC Invests $12.04 Million in Inhibrx, Inc. (NASDAQ:INBX)HighTower Advisors LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 781,752 shares of the company's stock, valued at approximately $12,039,000. HighMarch 17, 2025 | marketbeat.comInhibrx (INBX) to Release Quarterly Earnings on ThursdayInhibrx (NASDAQ:INBX) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Sees Significant Decline in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 1,220,000 shares, a drop of 5.4% from the January 15th total of 1,290,000 shares. Based on an average daily trading volume, of 86,400 shares, the days-to-cover ratio is presently 14.1 days. Approximately 12.3% of the shares of the stock are sold short.February 18, 2025 | marketbeat.comInhibrx (INBX) Expected to Announce Earnings on ThursdayInhibrx (NASDAQ:INBX) will be releasing earnings before the market opens on Thursday, February 13, Financial Modeling Prep reports.February 6, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 39,130 Shares of Inhibrx, Inc. (NASDAQ:INBX)JPMorgan Chase & Co. trimmed its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 88.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,135 shares of the company's stock after selling 39,130 shaFebruary 4, 2025 | marketbeat.comEmpirical Financial Services LLC d.b.a. Empirical Wealth Management Takes $348,000 Position in Inhibrx, Inc. (NASDAQ:INBX)Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 22,584 shaJanuary 30, 2025 | marketbeat.comInhibrx's SWOT analysis: oncology biotech stock faces pivotal year aheadJanuary 22, 2025 | msn.comInhibrx Biosciences Inc (INBX) Gets a Hold from JMP SecuritiesJanuary 22, 2025 | markets.businessinsider.comInhibrx (NASDAQ:INBX) Receives "Market Perform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a report on Wednesday.January 22, 2025 | marketbeat.comInhibrx reports promising ozekibart trial resultsJanuary 22, 2025 | msn.comInhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal CancerJanuary 21, 2025 | prnewswire.comInhibrx Biosciences Announces Loan Agreement with Oxford FinanceJanuary 13, 2025 | prnewswire.comInhibrx, Inc. (NASDAQ:INBX) Sees Large Increase in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,200,000 shares, a growth of 10.1% from the November 30th total of 1,090,000 shares. Currently, 12.1% of the company's stock are sold short. Based on an average daily trading volume, of 77,600 shares, the short-interest ratio is presently 15.5 days.December 31, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.8% in NovemberInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 1,090,000 shares, a growth of 5.8% from the November 15th total of 1,030,000 shares. Based on an average daily volume of 84,700 shares, the days-to-cover ratio is presently 12.9 days. Currently, 11.0% of the company's stock are sold short.December 16, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem Buys 69,686 SharesNovember 23, 2024 | insidertrades.comJon Faiz Kayyem Purchases 69,686 Shares of Inhibrx, Inc. (NASDAQ:INBX) StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) Director Jon Faiz Kayyem bought 69,686 shares of Inhibrx stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.November 22, 2024 | marketbeat.comInhibrx Biosciences, Inc. (INBX)November 22, 2024 | finance.yahoo.comThe recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the sharesNovember 21, 2024 | uk.finance.yahoo.comJMP Securities Sticks to Their Hold Rating for Inhibrx Biosciences Inc (INBX)November 18, 2024 | markets.businessinsider.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 9.0% in OctoberInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 976,700 shares, a growth of 9.0% from the October 15th total of 895,700 shares. Currently, 9.7% of the company's shares are short sold. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 10.9 days.November 17, 2024 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.deStocks Close Lower on Hawkish PowellNovember 14, 2024 | msn.comInhibrx Biosciences Inc (INBX)November 14, 2024 | investing.comInhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | prnewswire.comInhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformNovember 5, 2024 | seekingalpha.comInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationNovember 4, 2024 | prnewswire.comInhibrx Biosciences (NASDAQ:INBX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comInhibrx, Inc. (NASDAQ:INBX) Short Interest UpdateInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 742,500 shares, an increase of 9.6% from the September 15th total of 677,700 shares. Based on an average trading volume of 106,900 shares, the short-interest ratio is presently 6.9 days. Approximately 7.4% of the shares of the company are short sold.October 16, 2024 | marketbeat.comInhibrx CEO buys shares worth over $629kSeptember 19, 2024 | investing.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 13,037 SharesSeptember 17, 2024 | insidertrades.comDirector Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)September 13, 2024 | finance.yahoo.comInhibrx, Inc. (NASDAQ:INBX) CEO Purchases $144,495.00 in StockSeptember 11, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 SharesInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 9,500 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $15.21 per share, for a total transaction of $144,495.00. Following the transaction, the chief executive officer now owns 657,048 shares of the company's stock, valued at $9,993,700.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.September 10, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Acquires 10,000 SharesSeptember 4, 2024 | insidertrades.comInsider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Buys 10,000 Shares of StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 10,000 shares of the company's stock in a transaction on Thursday, August 29th. The stock was acquired at an average cost of $14.03 per share, with a total value of $140,300.00. Following the completion of the purchase, the chief executive officer now directly owns 135,000 shares in the company, valued at $1,894,050. The purchase was disclosed in a filing with the SEC, which is available at this link.September 3, 2024 | marketbeat.com Remove Ads Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address INBX Media Mentions By Week INBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼1.820.79▲Average Medical News Sentiment INBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼21▲INBX Articles Average Week Remove Ads Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News Cronos Group News Evolus News Xeris Biopharma News LENZ Therapeutics News Immunome News Rocket Pharmaceuticals News Xencor News Arbutus Biopharma News Pharvaris News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INBX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
